

ABSTRACT OF THE DISCLOSURE

Monoclonal antibodies that specifically bind to an extracellular domain of a *flt-1* receptor and neutralize activation of the receptor are provided. *In vitro* and *in vivo* methods of using these antibodies are also provided.

5